Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegnano + Barivir in Chronic Hepatitis C
NCT06922643Phase 4Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Mar 2011
- Primary completion
- Jan 2013
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
A Phase 4 trial of peginterferon alfa-2a in hepatitis C (HCV), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Started Mar 2011; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT06922643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922643.